KBC Group
WST icon

KBC Group’s West Pharmaceutical WST Stock Holding History

KBC Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
11,152
+1,542
+16% +$471K 0.01% 543
2026
Q1 		$2.41M Sell
9,610
-11,791
-55% -$2.93M 0.01% 629
2025
Q4 		$5.89M Buy
21,401
+10,077
+89% +$2.76M 0.01% 439
2025
Q3 		$2.97M Hold
11,324
– – 0.01% 527
2025
Q2 		$2.48M Buy
11,324
+712
+7% +$152K 0.01% 549
2025
Q1 		$2.38M Buy
10,612
+632
+6% +$174K 0.01% 564
2024
Q4 		$3.27M Buy
9,980
+42
+0.4% +$13.2K 0.01% 578
2024
Q3 		$2.98M Sell
9,938
-7,441
-43% -$2.28M 0.01% 546
2024
Q2 		$5.72M Sell
17,379
-1,964
-10% -$694K 0.02% 407
2024
Q1 		$7.65M Sell
19,343
-84,221
-81% -$31.2M 0.02% 376
2023
Q4 		$36.5M Sell
103,564
-8,006
-7% -$2.83M 0.13% 173
2023
Q3 		$41.9M Buy
111,570
+5,267
+5% +$2.04M 0.17% 130
2023
Q2 		$40.7M Buy
106,303
+60,230
+131% +$21.5M 0.17% 136
2023
Q1 		$16M Buy
46,073
+3,315
+8% +$969K 0.07% 275
2022
Q4 		$10.1M Sell
42,758
-22,042
-34% -$5.22M 0.05% 317
2022
Q3 		$15.9M Sell
64,800
-2,085
-3% -$635K 0.08% 240
2022
Q2 		$20.2M Sell
66,885
-963
-1% -$313K 0.1% 223
2022
Q1 		$27.9M Sell
67,848
-40,227
-37% -$15.7M 0.11% 202
2021
Q4 		$50.7M Sell
108,075
-1,678
-2% -$722K 0.17% 147
2021
Q3 		$46.6M Sell
109,753
-16,706
-13% -$7.04M 0.17% 141
2021
Q2 		$45.4M Sell
126,459
-5,233
-4% -$1.73M 0.16% 143
2021
Q1 		$37.1M Buy
131,692
+32,668
+33% +$9.35M 0.15% 170
2020
Q4 		$28.1M Sell
99,024
-55,819
-36% -$15.7M 0.13% 187
2020
Q3 		$42.6M Buy
154,843
+43,624
+39% +$11.5M 0.25% 92
2020
Q2 		$25.3M Buy
111,219
+59,546
+115% +$11.7M 0.17% 131
2020
Q1 		$7.87M Buy
51,673
+46,391
+878% +$7.14M 0.07% 284
2019
Q4 		$794K Buy
+5,282
New +$769K 0.01% 965

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

KBC Group's WST Position: Q2 2026 in Review

KBC Group increased its West Pharmaceutical (WST) stake by 16% in Q2 2026, buying an estimated $471K and bringing the position to 11,152 shares worth $4M. The position accounts for 0.01% of the portfolio, ranked #543.

KBC Group first reported a position in WST in Q4 2019 and has held it in 27 quarters since. The position peaked at $50.7M in Q4 2021. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • KBC Group held 11,152 shares of West Pharmaceutical worth $4M as of Q2 2026.
  • KBC Group bought 1,542 West Pharmaceutical shares in Q2 2026, an estimated $471K.
  • West Pharmaceutical made up 0.01% of KBC Group's portfolio in Q2 2026, its #543 holding.
  • KBC Group first reported a position in West Pharmaceutical in Q4 2019 and has held it in 27 quarters since.
  • KBC Group's West Pharmaceutical position peaked at $50.7M in Q4 2021.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.